The changing epidemiology of liver disease in HIV patients

AIDS Reviews

Volumn 15, Issue 1, 2013, Pages 25-31

  Soriano, Vincent ^a   Barreiro, Pablo ^a   Sherman, Kenneth E ^b  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Hepatitis B. Hepatitis delta; Hepatitis C. HIV; Hepatitis E. Antiviral therapy

Indexed keywords

AMINOTRANSFERASE; DIDANOSINE; HEPATITIS B VACCINE; INTERFERON; LAMIVUDINE; LIVER ENZYME; PEGINTERFERON; RIBAVIRIN; TENOFOVIR;

ALCOHOLIC FATTY LIVER; ANTIVIRAL THERAPY; BONE DEMINERALIZATION; CHRONIC HEPATITIS D; CHRONICITY; DELTA AGENT HEPATITIS; END STAGE LIVER DISEASE; FANCONI RENOTUBULAR SYNDROME; FRACTURE; HEPATITIS B; HEPATITIS C; HEPATITIS E; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; IMMUNE DEFICIENCY; INTRAVENOUS DRUG ABUSE; KIDNEY DISEASE; KIDNEY FAILURE; LIVER DISEASE; LIVER INJURY; LIVER TOXICITY; MALE HOMOSEXUALITY; MIXED INFECTION; NONALCOHOLIC FATTY LIVER; NONHUMAN; REVIEW; SEXUAL TRANSMISSION; SILENT TUBULAR DAMAGE; TOXIC HEPATITIS; VACCINATION; VIRUS TRANSMISSION;

AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; COINFECTION; DISEASE PROGRESSION; END STAGE LIVER DISEASE; FATTY LIVER; FEMALE; HEPATITIS B; HEPATITIS C; HEPATITIS D; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALE;

EID: 84877893973     PISSN: 11396121     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Weber R, Sabin C, Friis-Moller N, et al. Liver-related deaths in persons infected with the HIV: the D:A:D study. Arch Intern Med 2006;166: 1632-41.
2. Ruppik M, Ledergerber B, Rickenbach M, et al. Changing patterns of causes of death: SHCS, 2005 to 2009. 18th CROI, Boston, MA. Feb 27-March 2, 2011 [abstract 789].
3. Puoti M, Moioli MC, Travi G, Rosootti R. The burden of liver disease in HIV-infected patients. Semin Liver Dis 2012;32:103-13.
4. Soriano V, Puoti M, Sulkowski M, et al. Care of patients coinfected with HIV and HCV: 2007 updated recommendations from the HCV-HIV International Panel. AIDS 2007;21:1073-89.
5. Barreiro P, Vispo E, Labarga P, Soriano V. Management and treatment of chronic hepatitis C in HIV patients. Semin Liver Dis 2012; 32: 138-46.
6. Calle-Serrano B, Manns M, Wedemeyer H. Hepatitis delta and HIV infection. Semin Liver Dis 2012;32:120-9.
7. Soriano V, Puoti M, Peters M, et al. Care of HIV patients with chronic hepatitis B: updated recommendations from the HIV-HBV International Panel. AIDS 2008; 22:1399-410.
8. Sulkowski M, Thomas D, Chaisson R, Moore R. Hepatotoxicity associated with antiretroviral therapy in adults infected with HIV and the role of hepatitis C or B virus infection. JAMA 2000;283:74-80.
9. Soriano V, Puoti M, García-Gascó P, et al. Antiretroviral drugs and liver injury. AIDS 2008;22:1-13.
10. Jones M, Nuñez M. Liver toxicity of antiretroviral drugs. Semin Liver Dis 2012;32:167-76.
11. Soriano V, Sherman K, Rockstroh J, et al. Challenges and opportunities for hepatitis C drug development in HIV-HCV coinfected patients. AIDS 2011;25:2197-208.
12. Boesecke C, Rockstroh J. Acute hepatitis C in patients with HIV. Semin Liver Dis 2012;32:130-7.
13. Kaba M, Richet H, Ravaux I, et al. Hepatitis E virus infection in patients infected with HIV. J Med Virol 2010;83:1704-16.
14. Dalton H, Bendall R, Keane F, et al. Persistent carriage of hepatitis E virus in patients with HIV infection. N Engl J Med 2009;361:1025-7.
15. Vallet-Pichard A, Mallet V, Pol S. Non-alcoholic fatty liver disease and HIV infection. Semin Liver Dis 2012;32:158-66.
16. Perez-Cachafeiro S, del Amo J, Iribarren JA, et al. Decrease in serial prevalence of coinfection with HCV among HIV-infected patients in Spain, 1997-2006. Clin Infect Dis 2009;48:1467-70.
17. Samet J. Russia and HIV - beyond crime and punishment. Addiction 2011;106:1883-5.
18. Javaraman S, Chalabi Z, Perel P; Guerriero C, Roberts I. The risk of transfusion-transmitted infections in Sub-Saharan Africa. Transfusion 2010;50:433-42.
19. Van der Helm J, Prins M, del Amo J, et al. The hepatitis C epidemic among HIV-positive MSM: incidence estimates from 1990 to 2007. AIDS 2011;25:1083-91.
20. Mehta S, Genberg B, Astemborki J, et al. Limited uptake of hepatitis C treatment among injecting drug users. J Community 2008;33:126-33.
21. Lee M, Yang H, Lu S, et al. Chronic HCV infection increases mortality from hepatic and extrahepatic diseases: a community-based long-term prospective study. J Infect Dis 2012;206:469-77.
22. Thompson M, Aberg J, Hoy J, Telenti A, Benson C, Cahn P, et al. Antiretroviral treatment of adult HIV infection: 2012 recommendations of the International Antiviral Society-USA panel. JAMA 2012;308:387-402.
23. Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents. Department of Health and Human Services. Available at http://aidsinfo.nih.gov/ contentfiles/lvguidelines/AdultandAdolescentGL.pdf. Last accessed September 1st, 2012.
24. Department of Health and Human Services. Recommendations for the identification of hepatitis C virus chronic infection. CDC Fed Reg 2012; 77:30293.
25. Saifu H, Asch S, Goetz M, Smith J, Graber C, Schaberg D, Sun B. Evaluation of HIV and hepatitis C telemedicine clinics. Am J Manag Care 2012;18:207-212.
26. Easterbrook P, Sands A, Harmanci H. Challenges and priorities in the management of HIV/HBV and HIV/HCV coinfection in resource-limited settings. Semin Liver Dis 2012;32:147-57.
27. Thio C, Seaberg E, Skolasky R, et al. HIV-1, HBV and risk of liver-related mortality in the MACS. Lancet 2002;360:1921-6.
28. Dore G, Soriano V, Rockstroh J, et al. Frequent HBV rebound among HIV-HBV coinfected patients following antiretroviral treatment interruption. AIDS 2010;24:857-65.
29. Hoffmann C, Charalambous S, Martin D, et al. HBV infection and response to antiretroviral therapy (ART) in a South African ART program. Clin Infect Dis 2008;47:1479-85.
30. Labarga P, Barreiro P, Martin-Carbonero L, Rodriguez-Novoa S, Solera C, Medrano J, et al. Kidney tubular abnormalities in the absence of impaired glomerular function in HIV patients treated with tenofovir. AIDS 2009;23:689-96.
31. Bedimo R, Maalouf NM, Zhang S, Drechsler H, Tebas P. Osteoporotic fracture risk associated with cumulative exposure to tenofovir and other antiretroviral agents. AIDS 2012;26:825-31.
32. Soriano V, Grint D, d'Arminio-Monforte A, et al. Hepatitis delta in HIVinfected individuals in Europe. AIDS 2011; 25: 1987-92.
33. Yurgaydin C. Treatment of chronic delta hepatitis. Semin Liver Dis 2012; 32:237-44.
34. Sheldon J, Ramos B, Toro C, Rios P, Martinez-Alarcon J, Bottecchia M, et al. Does treatment of hepatitis B virus (HBV) infection reduce hepatitis delta virus (HDV) replication in HIV-HBV-HDV-coinfected patients? Antivir Ther 2008;13:97-102.
35. Martín-Carbonero L, Teixeira T, Poveda E, Plaza Z, Vispo E, Soriano V. Clinical and virological outcomes in HIV-infected patients with chronic hepatitis B on long-term nucleos(t)ide analogues. AIDS 2011;25:73-79.
36. Kamar N, Bendall R, Legrand-Abravanel F, et al. Hepatitis E. Lancet 2012;379:2477-88.
37. Kuniholm M, Purcell R, McQuillan G, Engle R, Wasley A, Nelson K. Epidemiology of hepatitis E virus in the United States: results from the Third National Health and Nutrition Examination Survey, 1988-1994. J Infect Dis 2009;200:48-56.
38. Atiq M, Shire N, Barrett A, Rouster S, Sherman K, Shata M. Hepatitis E virus antibodies in patients with chronic liver disease. Emerg Infect Dis 2009;15:479-81.
39. Wedemeyer H, Pischke S, Manns M. Pathogenesis and treatment of hepatitis E virus infection. Gastroenterology 2012;142:1388-97.
40. Kamar N, Selves J, Mansuy J, et al. Hepatitis E virus and chronic hepatitis in organ transplant recipients. N Engl J Med 2008;358:811-7.
41. Madejon A, Vispo E, Bottecchia M, Sanchez-Carrillo M, Garcia-Samaniego J, Soriano V. Lack of hepatitis E virus infection in HIV patients with advanced immunodeficiency or idiopathic liver enzyme elevations. J Viral Hepat 2009;16:895-6.
42. Vispo E, Mena A, Maida I, Blanco F, Cordoba M, Labarga P, et al. Hepatic safety profile of raltegravir in HIV-infected patients with chronic hepatitis C. J Antimicrob Chemother 2010;65:543-7.
43. Rockstroh J, Teppler H, Zhao J, Sklar P, Harvey C, Strohmaier K, et al. Safety and efficacy of raltegravir in patients with HIV-1 and hepatitis B and/or C virus coinfection. HIV Med 2012;13:127-31.
44. Maida I, Núñez M, Ríos MJ, Martín-Carbonero L, Sotgiu G, Toro C, et al. Severe liver disease associated with prolonged exposure to antiretroviral drugs. J Acquir Immune Defic Syndr 2006;42:177-82.
45. Mallet V, Blanchard P, Verkarre V, Vallet-Pichard A, Fontaine H, Lascoux-Combe C, et al. Nodular regenerative hyperplasia is a new cause of chronic liver disease in HIV-infected patients. AIDS 2007;21:187-92.
46. Kovari H, Ledergerber B, Peter U, Flepp M, Jost J, Schmid P, et al. Association of non-cirrhotic portal hypertension in HIV-infected persons and antiretroviral therapy with didanosine: a nested case-control study. Clin Infect Dis 2009;49:626-35.
47. Vispo E, Morello J, Rodriguez-Novoa S, Soriano V. Non-cirrhotic portal hypertension in HIV infection. Curr Opin Infect Dis 2011;24:12-8.
48. Vispo E, Cevik M, Rockstroh J, et al. Genetic determinants of idiopathic noncirrhotic portal hypertension in HIV-infected patients. Clin Infect Dis (in press)
49. Guaraldi G, Squillace N, Stentarelli C, et al. Non-alcoholic fatty liver disease in HIV-infected patients referred to a metabolic clinic: prevalence, characteristics and predictors. Clin Infect Dis 2008;47:250-7.
50. Ingiliz P, Valantin M, Duvivier C, et al. Liver damage underlying unexplained transaminases elevation in HIV-1 monoinfected patients on antiretroviral therapy. Hepatology 2009;49:436-42.
51. Ford N, Singh K, Cooke G, et al. Expanding Access to treatment for hepatitis in resource-limited settings: lessons from HIV/AIDS. Clin Infect Dis 2012;54:1465-72.